# Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure

> **NCT07259512** · PHASE4 · RECRUITING · sponsor: **Evi Liliek Wulandari** · enrollment: 80 (estimated)

## Conditions studied

- Chronic Kidney Disease
- Heart Failure With Reduced Ejection Fraction (HFrEF)

## Interventions

- **DRUG:** Ramipril

## Key facts

- **NCT ID:** NCT07259512
- **Lead sponsor:** Evi Liliek Wulandari
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-01-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07259512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07259512, "Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT07259512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*